Oncological study group
Main Fields of Research
The focus of our clinical research is studying how to optimize skin cancer treatment with immunotherapy, targeted therapy and local therapy options. In this context we conduct clinical studies including investigator initiated trials, with new compounds, combinations or treatment schemes. Additionally, we investigate the role of nutrition and the microbiome with respect to response and toxicity of immunotherapy. We assess how to break checkpoint inhibitor resistance with other immunotherapies, cellular therapies, targeted therapy and oncolytic viruses. We also assess modern imaging techniques for diagnostic procedures. Within our biomarker research we try to establish prognostic and predictive biomarkers.
Prof. Lucie Heinzerling,
MD, MPH
Larissa Akçetin, MD
Naghmeh Azadfar, Msc
Dagmar Dick, technician
Laura Engels, MD
Anne Gürtler, MD
Claudia Kammerbauer, technician
Sonja Maier, study coordinator
Farnaz Rahimi, MD
Cristel Ruini, MD
Suzanna Salzer, MD
Irina Schnaitter, nurse
Christine Straßer, study coordinator
Alexandra Walter, MD
» Daillère R, Derosa L, Bonvalet M, Segata N, Routy B, Gariboldi M, Budinská E, De Vries IJM, Naccarati AG, Zitvogel V, Caldas C, Engstrand L, Loilbl S, Fieschi J, Heinzerling L, Kroemer G, Zitvogel L (2020) Trial watch: the gut microbiota as a tool to boost the clinical efficacy of anticancer immunotherapy. Oncoimmunology 9(1):1774298
» Garbe C, Keim U, Suciu S, Amaral T, Eigentler TK, Gesierich A, Hauschild A, Heinzerling L, Kiecker F, Schadendorf D, Stadler R, Sunderkötter C, Tüting T, Utikal J, Wollina U, Zouboulis CC, Keilholz U, Testori A, Martus P, Leiter U, Eggermont AMM German Central Malignant Melanoma Registry and the European Organisation for Research and Treatment of Cancer (2020) Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts. J Clin Oncol 38(22):2543-51
» Zhang L, Zlotoff DA, Awadalla M, Mahmood SS, Nohria A, Hassan MZO, Thuny F, Zubiri L, Chen CL, Sullivan RJ, Alvi RM, Rokicki A, Murphy SP, Jones-O‘Connor M, Heinzerling LM, Barac A, Forrestal BJ, Yang EH, Gupta D, Kirchberger MC, Shah SP, Rizvi MA, Sahni G, Mandawat A, Mahmoudi M, Ganatra S, Ederhy S, Zatarain-Nicolas E, Groarke JD, Tocchetti CG, Lyon AR, Thavendiranathan P, Cohen JV, Reynolds KL, Fradley MG, Neilan TG (2020) Major Adverse Cardiovascular Events and the Timing and Dose of Corticosteroids in Immune Checkpoint Inhibitor-Associated Myocarditis. Circulation 141(24):2031-34 3
» Heinzerling L, Eigentler TK, Fluck M, Hassel JC, Heller-Schenck D, Leipe J, Pauschinger M, Vogel A, Zimmer L, Gutzmer R (2019) Tolerability of BRAF/MEK inhibitor combinations: Adverse event evaluation and management. ESMO Open, 4(3),e000491
» Kirchberger MC, Ugurel S, Mangana J, Heppt MV, Eigentler TK, Berking C, Schadendorf D, Schuler G, Dummer R, Heinzerling L (2018) MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicenter analysis of 364 patients. Eur J Cancer, 98:10-6
